Andere talen Kintor Pharmaceutical Limited

Aandelen

9939

KYG5273B1077

Vertraagde tijd Hong Kong S.E. Andere beurzen 04:44:02 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,32 ^HKD	-1,49%		+8,20%	-19,02%

04/06	Kintor Pharma ontvangt standaardnaam voor cosmetisch ingrediënt voor KX-826 product	MT
04/06	Kintor Pharmaceutical Limited kondigt aan dat Kx-826 de Inci aanwijzing ontvangt	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product	04/06
Kintor Pharmaceutical Limited Announces Kx-826 Receives the Inci Designation	04/06
Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%	24/05
Kintor Pharmaceutical Limited Announces That the Clinical Trial of Its In-House Developed and Potential First-In-Class Kx-826 Tincture 1.0% for the Treatment of Male Adult Androgenetic Alopecia ("Aga") in China (The "Clinical Trial") Was Cleared by the National Medical Products Administration (The "Nmpa") Recently	24/05
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint	22/04
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment	22/04
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator	01/02
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA	01/02
Kintor Pharmaceutical's Phase 3 Trial for Alopecia Treatment Promotes Hair Growth; Shares Plunge 30%	27/11
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia	27/11
Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	28-10-23
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11-10-23
Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	11-10-23
Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	28-08-23
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28-08-23
Kintor Pharmaceutical Completes Enrollment for Alopecia Drug Trial	23-08-23
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China	22-08-23
Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	22-08-23
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	20-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kintor Pharmaceutical Limited

Aandelen

9939

KYG5273B1077

Andere talen

Filters